What changed from existing technology?
This study shows that EGCG, a compound found in green tea, can stop gastric cancer cells from spreading by affecting a specific cell signaling pathway called the Hedgehog pathway.
This is the first study to demonstrate that EGCG targets the Hedgehog signaling pathway to inhibit gastric cancer cell invasion and migration.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
geting the Hedgehog signaling pathway. Gastric cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for eff
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
EGCG may have potential as a therapeutic agent for gastric cancer by targeting the Hedgehog signaling pathway, though further clinical studies are needed.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.